Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/detail.php on line 234

Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 82

Warning: array_push() expects parameter 1 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 85
Pharmalicensing | Life Science's Global Technology Marketplace
Save this technology
close
Save to Existing Project
Save to a New Project
Compositions for Inhibitors of QSOX1: Combating Cancer Progression and Metastatic Disease
Yeda R&D Co. Ltd Israel flag Israel
Abstract ID: 1642
Cancer is the second leading cause of death in the US, accounting for roughly 23% of all deaths (as of 2008), and with estimated cost of care of...
Contact
Participants
You
Email me a copy of this message
Introduction/Background

Cancer is the second leading cause of death in the US, accounting for roughly 23% of all deaths (as of 2008), and with estimated cost of care of $157 billion (as of 2010). Despite major advances in the management of cancer, most types of solid tumours remain resistant to conventional treatment modalities. The local microenvironment, or niche, of a cancer cell plays important roles in cancer development. A major component of the niche is the extracellular matrix (ECM), a rich mesh of fibrous proteins surrounding cells that has been shown to exert a protective and supporting effect on cancer progression.

Aims/Hypothesis

Therefore, targeting the ECM represents a novel avenue for rational anticancer drug design.

Results

A team of researchers at the Weizmann Institute have that a secreted disulfide bond catalyst known as Quiescin sulfhydryl oxidase 1 (QSOX1) is required for proper assembly of the ECM. The main substrates of QSOX1 within the ECM are laminins. Thus, cells lacking QSOX1 show poor incorporation of laminin into the ECM mesh, resulting in decreased cell adherence and perturbed cell migration. Notably, in some cancer types such as pancreatic and breast cancers, QSOX1 and the ECM components it produces are over-expressed. This suggests that modulation of QSOX1 activity may provide a novel means to combating cancer and metastasis. Treatment of cancer cells with a monoclonal QSOX1-targeting antibody effectively blocked cell migration and provides a novel strategy for cancer treatment by QSOX1 inhibition.

Conclusion

The current technology allows for specific targeting of an enzyme that takes part in ECM assembly and maintenance, and may provide a novel means for combating cancer progression and metastasis emergence.

Relevance/Opportunity

Please enquire quoting reference no. 1642 regarding licensing or codevelopment partnerships.
FEATURED
Last Updated May 2015
Technology Type THERAPEUTIC
Phase of Development PRECLINICAL
CORPORATION